Abstract
Cyclosporine A (CsA) is effective in treating moderate-to-severe atopic dermatitis (AD). However, several side effects have been reported. This systematic review and meta-analysis aimed to summarize the effectiveness and safety of low-dose versus high-dose CsA and other systemic immunomodulatory agents in patients with AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
